Ipsen (IPN.PA) And GW Pharmaceuticals Enter Into Agreement For Ipsen To Promote And Distribute Sativex® In Latin America
1/14/2014 8:51:25 AM
LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:
Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical company, and GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announce that they have entered into an exclusive agreement for Ipsen to promote and distribute Sativex®1, a sublingual cannabis extract spray intended for the treatment of spasticity due to multiple sclerosis (MS) in Latin America (excluding Mexico and the Islands of the Caribbean). GW will be responsible for commercial product supply to Ipsen.
Help employers find you! Check out all the jobs and post your resume.
comments powered by